$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000144702820000038 Filed on March 05, 2020

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q2
Revenue	$1.618M	$3.061M	$653.0K
YoY Change	-3.58%	92.88%	-47.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.880M	$3.250M	$8.190M
YoY Change	-68.3%	23.57%	116.67%
% of Gross Profit
Research & Development	$12.42M	$17.73M	$12.74M
YoY Change	12.3%	7.03%	-22.11%
% of Gross Profit
Depreciation & Amortization	$510.0K	$507.0K	$505.0K
YoY Change	2.0%	2.01%	-12.63%
% of Gross Profit
Operating Expenses	$14.80M	$94.09M	$21.30M
YoY Change	-15.43%	176.62%	-8.55%
Operating Profit	-$13.09M	-$91.03M	-$20.65M
YoY Change	-22.58%	180.72%	-6.35%
Interest Expense	-$11.57M	$1.100M	$2.000K
YoY Change	386.13%
% of Operating Profit
Other Income/Expense, Net		-$4.134M	-$2.670M
YoY Change		-212.61%	-110.62%
Pretax Income	-$24.65M	-$95.16M	-$23.32M
YoY Change	35.07%	230.93%	-854.29%
Income Tax	$0.00	-$12.66M	$0.00
% Of Pretax Income
Net Earnings	-$24.65M	-$82.50M	-$23.32M
YoY Change	35.1%	237.12%	-854.29%
Net Earnings / Revenue	-1523.73%	-2695.3%	-3570.44%
Basic Earnings Per Share	-$0.46	-$1.50	-$0.46
Diluted Earnings Per Share	-$418.0K	-$1.451M	-$0.46
COMMON SHARES
Basic Shares Outstanding	56.85M shares	56.85M shares	56.81M shares
Diluted Shares Outstanding			56.81M shares

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.83M	$90.10M	$95.30M
YoY Change	-27.1%	-36.55%	-38.48%
Cash & Equivalents	$31.80M	$90.08M	$78.87M
Short-Term Investments	$59.04M	$0.00	$16.40M
Other Short-Term Assets	$1.800M	$1.800M	$2.800M
YoY Change	-35.71%	63.64%	133.33%
Inventory
Prepaid Expenses
Receivables	$1.204M	$2.488M	$1.531M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$93.83M	$94.34M	$99.58M
YoY Change	-27.39%	-34.5%	-36.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.676M	$9.150M	$9.402M
YoY Change	-14.48%	-12.2%	-11.97%
Goodwill	$0.00	$0.00	$22.47M
YoY Change	-100.0%	-100.0%	0.0%
Intangibles	$0.00	$0.00	$43.84M
YoY Change	-100.0%	-100.0%	-25.25%
Long-Term Investments	$0.00	$10.97M	$14.38M
YoY Change	-100.0%	-55.53%	-47.62%
Other Assets	$293.0K
YoY Change
Total Long-Term Assets	$11.71M	$22.94M	$92.99M
YoY Change	-88.14%	-77.38%	-22.02%
TOTAL ASSETS
Total Short-Term Assets	$93.83M	$94.34M	$99.58M
Total Long-Term Assets	$11.71M	$22.94M	$92.99M
Total Assets	$105.5M	$117.3M	$192.6M
YoY Change	-53.69%	-52.21%	-30.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.400M	$1.400M	$700.0K
YoY Change	-25.0%	-54.84%	-78.13%
Accrued Expenses	$5.200M	$7.300M	$8.000M
YoY Change	-31.58%	17.74%	50.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.828M	$8.817M	$8.799M
YoY Change	-30.35%	-30.4%	-23.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.00M	$24.80M	$6.600M
YoY Change	557.89%	416.67%	-37.14%
Total Long-Term Liabilities	$25.00M	$24.80M	$6.600M
YoY Change	557.89%	416.67%	-37.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.828M	$8.817M	$8.799M
Total Long-Term Liabilities	$25.00M	$24.80M	$6.600M
Total Liabilities	$32.79M	$33.64M	$28.10M
YoY Change	18.5%	11.59%	-27.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$970.1M	-$942.6M	-$857.3M
YoY Change	20.48%	20.17%	13.2%
Common Stock	$898.5M	$884.6M	$884.6M
YoY Change	2.18%	0.66%	0.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.74M	$83.64M	$164.5M
YoY Change
Total Liabilities & Shareholders Equity	$105.5M	$117.3M	$192.6M
YoY Change	-53.69%	-52.21%	-30.48%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	-$24.65M	-$82.50M	-$23.32M
YoY Change	35.1%	237.12%	-854.29%
Depreciation, Depletion And Amortization	$510.0K	$507.0K	$505.0K
YoY Change	2.0%	2.01%	-12.63%
Cash From Operating Activities	-$13.35M	-$23.47M	-$17.61M
YoY Change	-21.84%	77.75%	-0.1%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	$255.0K	$240.0K
YoY Change	-73.91%	7.59%	-43.53%
Acquisitions
YoY Change
Other Investing Activities	-$58.76M	$16.41M	$10.22M
YoY Change	-230.55%	36.64%	-33.68%
Cash From Investing Activities	-$58.82M	$16.16M	$9.972M
YoY Change	-231.35%	-33.73%	-33.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$2.477M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.90M	$18.55M	$2.479M
YoY Change	12536.36%	4164.14%	237.28%
NET CHANGE
Cash From Operating Activities	-13.35M	-$23.47M	-$17.61M
Cash From Investing Activities	-58.82M	$16.16M	$9.972M
Cash From Financing Activities	13.90M	$18.55M	$2.479M
Net Change In Cash	-58.27M	$11.21M	-$5.097M
YoY Change	-309.53%	-4.51%	124.74%
FREE CASH FLOW
Cash From Operating Activities	-$13.35M	-$23.47M	-$17.61M
Capital Expenditures	-$60.00K	$255.0K	$240.0K
Free Cash Flow	-$13.29M	-$23.73M	-$17.85M
YoY Change	-21.13%	76.51%	-1.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	472000	USD
CY2019	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	180000	USD
CY2019	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2714000	USD
CY2019	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2018Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	608000	USD
CY2018Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2341000	USD
CY2019Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2314000	USD
CY2018Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2716000	USD
CY2019Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1433000	USD
CY2019Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	914000	USD
CY2018Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	0	USD
CY2019Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	5128000	USD
CY2018Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	147000	USD
CY2019Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	705000	USD
CY2018Q4	abus	Deferred Tax Asset Upfront License Fees DeferredTaxAssetUpfrontLicenseFees	283000	USD
CY2019Q4	abus	Deferred Tax Asset Upfront License Fees DeferredTaxAssetUpfrontLicenseFees	236000	USD
CY2018Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	479000	USD
CY2019Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	253000	USD
CY2018Q4	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	479000	USD
CY2019Q4	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	253000	USD
CY2019	abus	Fixed Lease Cost FixedLeaseCost	900000	USD
CY2018	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-7298000	USD
CY2019	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-173000	USD
CY2019	abus	Interestrateonrestrictedinvestment Interestrateonrestrictedinvestment	0.0875
CY2019Q4	abus	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	18992000	USD
CY2019Q3	abus	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	0	USD
CY2018Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	0	USD
CY2019Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18992000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9330000	CAD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
CY2018	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	19557000	USD
CY2019	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	-22522000	USD
CY2018	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	0	USD
CY2019Q4	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	2	lease
CY2019Q3	abus	Liability From Sale Of Future Royalties Additions LiabilityFromSaleOfFutureRoyaltiesAdditions	30000000	USD
CY2019	abus	Liability From Sale Of Future Royalties Discounts And Issuance Costs LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts	11451000	USD
CY2019	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	2099000	USD
CY2019	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	1656000	USD
CY2019	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	1656000	USD
CY2019	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	2099000	USD
CY2018	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	USD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2013Q4	abus	Number Of Executive Officers Granted Options With New Appointments NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments	2	executive_officers
CY2018	abus	Otherincome Netequityinvestmentgainorloss OtherincomeNetequityinvestmentgainorloss	19322000	USD
CY2019	abus	Otherincome Netequityinvestmentgainorloss OtherincomeNetequityinvestmentgainorloss	-22522000	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2018	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2019	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	18549000	USD
CY2016Q4	abus	Restricted Investment Term RestrictedInvestmentTerm	P2Y
CY2019	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2018Q4	abus	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Fair Value Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingFairValuePrice	1.27
CY2019Q4	abus	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Fair Value Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingFairValuePrice	1.11
CY2018	abus	Strightline Fixed Lease Cost StrightlineFixedLeaseCost	1400000	USD
CY2019Q4	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68941406	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	118248358	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9429000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7098000	USD
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3192000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2398000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1431000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1204000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	275000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	871000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	809000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6896000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5642000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48170000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48229000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48084000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55246000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6687000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1131000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7204000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6007000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6799000	USD
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24717000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28357105	shares
CY2018Q4	us-gaap	Assets Assets	227905000	USD
CY2019Q4	us-gaap	Assets Assets	105535000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	129229000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	93828000	USD
CY2019Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	100000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-7298000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-200000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3126000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2953000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54292000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36942000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31799000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17350000	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5143000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2019Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55518800	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64789314	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55518800	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64789314	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	879405000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	898535000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57045000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-153782000	USD
CY2018	us-gaap	Contribution Of Property ContributionOfProperty	27377000	USD
CY2019	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4282000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	645000	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	37000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3038000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71024000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	102762000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15803000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16349000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51575000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	59956000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11040000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11726000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2503000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6202000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4265000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3897000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	307000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	202000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83685000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	102762000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	12661000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	12664000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0	USD
CY2018	us-gaap	Depreciation Depreciation	2181000	USD
CY2019	us-gaap	Depreciation Depreciation	2028000	USD
CY2018	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	10091000	USD
CY2019	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11149000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.50
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.89
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1003000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	68000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6846000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P25M
CY2019Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.40
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22224000	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1003000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	41000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1003000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	68000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-20000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16002000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17727000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	22471000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22500000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22471000	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	22500000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14811000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43836000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61342000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-166379000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4282000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12656000	USD
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-12700000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13062000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19078000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8356000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-138000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-3343000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-16563000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44922000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	4719000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1685000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	523000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-2328000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3458000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1266000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2410000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1029000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-227000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-128000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2742000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	49000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-665000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	648000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1606000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2111000	USD
CY2018	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	1331000	USD
CY2019	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-983000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	0	USD
CY2018	us-gaap	Interest Expense InterestExpense	226000	USD
CY2019	us-gaap	Interest Expense InterestExpense	2108000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	104000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	3047000	USD
CY2018	us-gaap	Legal Fees LegalFees	0	USD
CY2019	us-gaap	Legal Fees LegalFees	6266000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4552000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1423000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	657000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	616000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	598000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	581000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	677000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1193000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	27671000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	32791000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	227905000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105535000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11239000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7828000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55646000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37457000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4127000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28338000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67866000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71006000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	3091000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-24473000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-18249000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-57060000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-23251000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23315000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-82503000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-24654000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-153723000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19765000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	550000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27040000	USD
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20896000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67151000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25966000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26077000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85295000	USD
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27534000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-164872000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28438000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22305000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	95725000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	150085000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18405000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22046000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32426000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-16903000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-89780000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19071000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20515000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-91401000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-13087000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-144074000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3359000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	340000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	USD
CY2018	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1116000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2738000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y0M1D
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	309000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	144000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	293000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-59000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-59000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	121580000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	58759000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1138000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	589000	USD
CY2018	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2019	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	10091000	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	11149000	USD
CY2018Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	126136000	USD
CY2019Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	137285000	USD
CY2018Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2019Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3181000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1790000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18601000	USD
CY2018	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66265000	USD
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	118566000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	87675000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1382000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	307000	USD
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3400000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17041000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14318000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10145000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8676000	USD
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57934000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57601000	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	4797000	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	156000	USD
CY2018	us-gaap	Restructuring Costs RestructuringCosts	396000	USD
CY2019	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	137000	USD
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1331000	USD
CY2019Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	137000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805221000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-970093000	USD
CY2018Q1	us-gaap	Revenues Revenues	1436000	USD
CY2018Q2	us-gaap	Revenues Revenues	1244000	USD
	us-gaap	Revenues Revenues	1587000	USD
CY2018Q4	us-gaap	Revenues Revenues	1678000	USD
CY2018	us-gaap	Revenues Revenues	5945000	USD
CY2019Q1	us-gaap	Revenues Revenues	679000	USD
CY2019Q2	us-gaap	Revenues Revenues	653000	USD
CY2019Q3	us-gaap	Revenues Revenues	3061000	USD
CY2019Q4	us-gaap	Revenues Revenues	1618000	USD
CY2019	us-gaap	Revenues Revenues	6011000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6241000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6799000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7520
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1310
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0248
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0159
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2424703	shares
CY2018Q4	us-gaap	Share Price SharePrice	3.83
CY2019Q4	us-gaap	Share Price SharePrice	2.78
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y0M
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y2M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y7M
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	87675000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	59035000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18601000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1382000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	307000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	200234000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	72744000	USD
CY2018	us-gaap	Sublease Income SubleaseIncome	200000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	200000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	300000	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue our strategy of developing a treatment for chronic HBV, we are developing a diverse product pipeline consisting of multiple drug candidates with complementary mechanisms of action, which have the potential to improve upon the SOC and contribute to a curative combination regimen. Our pipeline includes agents that have the potential to form an effective proprietary combination therapy. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s pipeline includes:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AB-729, a subcutaneously-delivered RNA interference (“RNAi”) therapeutic product candidate currently in a Phase 1a/1b clinical trial with preliminary results anticipated in late March 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AB-836, a next-generation capsid inhibitor product candidate currently advancing through IND-enabling studies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other compounds early in the development process, including back-up capsid inhibitors, next-generation oral HBV RNA destabilizers and compounds that inhibit PD-L1.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses and contingent liabilities as of the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to valuation of intangible assets and goodwill, stock-based compensation, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div></div>

Files In Submission

Name	View Source	Status
0001447028-20-000038-index-headers.html	Edgar Link	pending
0001447028-20-000038-index.html	Edgar Link	pending
0001447028-20-000038.txt	Edgar Link	pending
0001447028-20-000038-xbrl.zip	Edgar Link	pending
abus-20191231.xml	Edgar Link	completed
abus-20191231.xsd	Edgar Link	pending
abus-20191231_cal.xml	Edgar Link	unprocessable
abus-20191231_def.xml	Edgar Link	unprocessable
abus-20191231_lab.xml	Edgar Link	unprocessable
abus-20191231_pre.xml	Edgar Link	unprocessable
abushbvpipeline021020.jpg	Edgar Link	pending
arbutus10k2019.htm	Edgar Link	pending
exhibit211_listingofsubsid.htm	Edgar Link	pending
exhibit231_kpmgconsent2019.htm	Edgar Link	pending
exhibit2322019consent.htm	Edgar Link	pending
exhibit311_10-kcertceo2019.htm	Edgar Link	pending
exhibit312_10-kcertcfo2019.htm	Edgar Link	pending
exhibit321_soxcertceo2019.htm	Edgar Link	pending
exhibit322_soxcertcfo2019.htm	Edgar Link	pending
exhibit42descriptionofsecu.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
inkedhbvlifecycleli.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2019 Q4 Form 10-K Financial Statement

#000144702820000038 Filed on March 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2019 Q4 Form 10-K Financial Statement

#000144702820000038 Filed on March 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus